Cepheid (CPHD +1%) continues its upward trajectory today, having gained over 17% since last...
Cepheid (CPHD +1%) continues its upward trajectory today, having gained over 17% since last Thursday. Credit Suisse says it remains a top SMID cap pick given its best-in-class diagnostic testing platform and strong secular growth trends. Shares are Outperform rated with a $45 price target.
From other sites
at Zacks.com (Mar 27, 2015)
at 4-traders.com (Mar 24, 2015)
at Investor's Business Daily (Jan 14, 2015)
at Nasdaq.com (Jan 6, 2015)
at Benzinga.com (Dec 18, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs